This phenomenon may reflect some uncertainty about the efficacy of SGLT2 inhibition in those with more advanced CKD, and inertia in changes in practice owing to the time taken for regulatory/payer approvals. The gene discussed is SLC5A2; the disease is chronic kidney disease.